Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein
- 15 September 2004
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 6 (10) , 1082-1091
- https://doi.org/10.1002/jgm.605
Abstract
Background Malignant glioma has a dismal prognosis. It was previously shown that glioma cells are efficiently killed when they express a gene coding for a hyperfusogenic mutant of the gibbon ape leukemia virus envelope glycoprotein (GALV.fus). However, production of viral vectors expressing GALV.fus has proven problematic because the transgene is toxic to vector‐producing cells of human origin. We reasoned that Sindbis‐virus‐based vectors might be ideal for GALV.fus gene transfer because high‐titer stocks can easily be generated in hamster cells and Sindbis virus efficiently infects human tumor cells through the high‐affinity 67 kDa laminin receptor. In addition, Sindbis virus nonstructural proteins are potent inducers of apoptosis, and Sindbis vector RNAs expressing fusogenic viral proteins have been shown to spread from cell‐to‐cell in membrane‐formed infectious particles. Methods Sindbis virus replicon‐containing particles were generated by co‐transfecting vector and helper RNAs into baby hamster kidney (BHK‐21) cells. Packaged beta‐galactosidase and GALV.fus expressing Sindbis vectors were used to infect glioma cell lines, which were then compared for syncytial cytopathic effect, cell killing, and release of infectious virus‐like particles containing the vector genome. Finally, the efficacy of GALV.fus and beta‐galactosidase Sindbis vectors was compared in an orthotopic intracerebral U87 glioma xenograft model in nude mice. Results High‐titer stocks (>109 infectious units (iu)/ml) of the GALV.fus and beta‐galactosidase vectors were obtained. Glioma cells infected with the GALV.fus vector formed large syncytia which died rapidly by apoptosis and released infectious membrane‐formed particles that could transfer vector genomes to uninfected cells. The GALV.fus vector had significantly greater antitumor therapeutic potency than the β‐galactosidase vector in the U87 glioma xenograft model. Conclusions Sindbis vectors expressing GALV.fus can be packaged into infectious viral particles to high titer, they exhibit potent bystander cytopathic potential and are active against U87 glioma xenografts. Sindbis‐virus‐based replicons appear to be efficient vector systems for delivery and expression of fusogenic membrane glycoproteins. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- Systemic tumor targeting and killing by Sindbis viral vectorsNature Biotechnology, 2003
- Heat-Directed Tumor Cell FusionHuman Gene Therapy, 2003
- Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma modelGene Therapy, 2002
- A Hyperfusogenic Gibbon Ape Leukemia Envelope Glycoprotein: Targeting of a Cytotoxic Gene by Ligand DisplayHuman Gene Therapy, 2000
- Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991Journal of Neurosurgery, 1998
- Expression of the 67 kD Laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5European Journal Of Cancer, 1996
- In VivoReplication-Deficient Adenovirus Vector-Mediated Transduction of the Cytosine Deaminase Gene Sensitizes Glioma Cells to 5-FluorocytosineHuman Gene Therapy, 1996
- Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNACell, 1994
- Growth Inhibition of Glioma Cells by Liposome-mediated Cell Transfection with Tumor Necrosis Factor-α GeneNeurologia medico-chirurgica, 1992
- Beitrag zur kollektiven Behandlung pharmakologischer ReihenversucheNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1931